LDS/Medical Tests/SERPINA1 Gene Mutation Analysis

SERPINA1 Gene Mutation Analysis

The SERPINA1 gene, located in the long (q) arm of chromosome 14 at position 32.13 encodes alpha-1 antitrypsin or α1-antitrypsin (A1AT, α1AT, A1A, or AAT). Alpha-1 antitrypsin (A1AT) belongs to the member of the serine proteinase inhibitor (serpin) family of proteins with a broad spectrum of biological functions including inhibition of proteases, immune modulation, and the transport of hormones. A1AT is an acute phase protein secreted by the liver and plays a key role in protecting the lower respiratory tract from proteolytic damage by inhibiting neutrophil elastase. A1AT is also synthesized in phagocytic cells, such as neutrophils, monocytes, and macrophages; lung epithelial cells; and intestinal cells. There are three major alleles of AAT; M (full functioning, normal allele), S (associated with reduced levels of protein), and Z (disease-causing mutation associated with liver disease and premature emphysema).

Mutations or pathogenic variants in SERPINA1 gene cause A1AT deficiency which is typically inherited as an autosomal codominant condition and occurs in approximately 1 in 2500 individuals. This condition is found in all ethnic groups; however, it occurs most often in whites of European ancestry. Due to the lack of functional A1AT, neutrophil elastase damages pulmonary alveoli, causing emphysema. Since it is an autosomal codominant disorder, individuals with A1AT deficiency have one normal copy and one mutated copy or two mutated copies. Most individuals who have one normal gene can produce enough AAT to live healthy lives, especially if they do not smoke. People who have two mutated genes are not able to produce A1AT resulting in the early development of emphysema. The most common mutation that causes A1AT deficiency, replaces the amino acid glutamic acid with the amino acid lysine at protein position 342 (Glu342Lys or E342K). Pathogenic variants in SERPINA1 can also cause accumulation of abnormal proteins in hepatocytes leading to liver disease. depending on the mutations/alleles involved the liver damage ranges from mild sub clinic hepatitis to hepatic cirrhosis and hepatocellular carcinoma. A1AT deficiency may be diagnosed by measuring serum levels of AAT and protease inhibitor (PI) typing.

Additionally, detection of SERPINA1 pathogenic variants can confirm a diagnosis of A1AT deficiency when serum AAT levels are not measured, PI typing is not performed, or results from serum AAT levels or PI typing are discordant. The majority of patients with A1AT deficiency have the PI-S or PI-Z alleles. The PI-S allele causes a structurally abnormal A1AT with mild functional impact and low disease risk, unless combined with other pathogenic alleles. The PI-Z allele also encodes a structurally abnormal form of AAT with more severe dysfunction associated with higher risk of lung and liver disease. Approximately 95% of individuals with clinical manifestations of A1AT deficiency have the PI-ZZ genotype.

  • Diagnostic confirmation of alpha-1 antitrypsin deficiency
  • Treatment selection and disease management
  • Carriers in family members and high-risk individuals

Abnormal

Detection of pathogenic alleles PI-S and PI-Z in SERPINA1 gene

  • MM – normal genotype, 100% A1A level
  • MS – 80% of normal A1A level
  • SS – 60% of normal A1A level
  • MZ – 55% of normal A1A level; in some studies, this genotype is statistically more common in the group of cryptogenic liver cirrhosis
  • SZ – 40% of normal A1A level; increased risk of lung and liver disease
  • ZZ – 15% of normal A1A level; clinically most prominent phenotype associated with early pulmonary emphysema (among approximately 35-year-old individuals), cryptogenic liver cirrhosis, juvenile liver cirrhosis, hepatocellular carcinoma
  • ZZ or SZ genotype – clinical manifestations of A1A.

Normal genotype PI-M

Targeted variant analysis by next generation sequencing for detecting the pathogenic alleles, Sequence analysis by Sanger sequencing of the regions of SERPINA1 gene containing mutations, SERPINA1 gene-targeted deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA), chromosomal microarray (CMA).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Liver biopsy, immunohistochemistry, PAS-positive, serum concentration of alpha-1 antitrypsin (A1AT), protease inhibitor (PI) typing, Pulmonary function tests, liver function tests, serum aminotransferase levels, comprehensive metabolic panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • PLoS One. 2012; 7(12): e51762. [PMID: 23251618]
  • J Mol Diagn. 2015;1: 689-94. [PMID: 26321041]
  • Curr Mol Med. 2012;12: 827-35. [PMID: 22697349]
  • Semin Respir Crit Care Med. 2005;26: 154-66. [PMID: 16088434]
  • Thorax. 2004;59: 529-35. [PMID: 15170041]
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/SERPINA1#
  • Chang-Hui Shen. Diagnostic molecular biology. In: chapter 14- molecular diagnosis of mutation and inherited disease. 2019: 359-386. https://doi.org/10.1016/B978-0-12-802823-0.00014-6